美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

美國抗疫概念

1,839.06

+18.751.03%

漲家數：11

跌家數：7

平家數：- -

市盈率：- -

高：1,844.35

開：1,819.74

低：1,815.03

收：1,820.31

成交量：9,802.34萬

成交額：64.71億

市值：1.50萬億

流通市值：1.48萬億

資料載入中...

總覽新聞資訊

輝瑞與 Sciwind Biosciences 達成糖尿病藥物交易

先為達生物攜手輝瑞中國，達成埃諾格魯肽商業化戰略合作協議

拜耳就前列腺癌藥物營銷問題起訴強生

BRIEF-中國先為達生物將向輝瑞收取至多4.95億美元，輝瑞獲其減肥藥在中國大陸的獨家商業化權益

專欄-諾華公司悄然解決亨麗埃塔-拉克斯訴訟案，家族的法律推動力日益壯大

杭州Sciwind生物與輝瑞中國就新一代Ecnoglutide注射劑商業化達成戰略合作協議

Vir Biotechnology公布企業動態及2025年第四季度與全年財務業績

Vir Biotechnology：在≥3000微克/公斤Q3W劑量隊列中，VIR-5500實現82%的PSA50及53%的PSA90下降率，並獲得RECIST可評估的客觀緩解

Vir Biotechnology發布靶向PSMA的Pro-Xten®雙遮蔽T細胞銜接器VIR-5500治療轉移性前列腺癌的積極1期最新數據

Vir Biotechnology, Inc.：推進劑量擴展隊列，計劃於2027年啓動註冊性試驗

安斯泰來與維爾合作開發前列腺癌實驗藥物

安斯泰來：有望獲得最高13.7億美元額外開發、監管及銷售里程碑款項

安斯泰來製藥與Vir Biotechnology達成全球戰略合作共同推進前列腺癌治療藥物VIR-5500研發

安斯泰來與Vir Biotechnology達成協議：後者將獲3.35億美元首付款及近期里程碑款項，雙方在美盈虧平分

安斯泰來：根據Vir Biotechnology與賽諾菲的授權協議條款，部分合作收益將分享給賽諾菲

美國 FDA 局長馬卡里説，FDA 支持 mRNA 疫苗，但美國納税人不應承擔費用

歐盟批准皮下注射版Rybrevant®▼（Amivantamab）用於晚期EGFR突變非小細胞肺癌患者的每三周及每四周給藥方案

強生皮下注射版Amivantamab獲准用於所有先前獲批的靜脈注射適應症

拜耳起訴強生公司虛假營銷前列腺癌藥物

肺病藥物後期試驗失敗，歌美颯生物股價暴跌

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4568/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美國抗疫概念","latestPrice":1839.0577,"timestamp":1771880399999,"preClose":1820.3057,"halted":0,"volume":98023433,"delay":0,"changeRate":0.010302,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":18.752075,"latestTime":"02-23 16:00:00 EST","open":1819.7351,"high":1844.3469,"low":1815.031,"amount":6470786377.296041,"amplitude":0.016105,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771923600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.576431,"peRate":26.855529,"turnoverRate":0.007083,"increases":11,"decrements":7,"flats":0,"marketCap":1503745191758.25,"floatMarketCap":1479908328347.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1844.3469,"amplitude":0.016105,"preClose":1820.3057,"low":1815.031,"pbRate":"4.576431","latestPrice":1839.0577,"volume":98023433,"delay":0,"open":1819.7351,"prevYearClose":1637.1339,"prevWeekClose":1820.3057,"prevMonthClose":1721.4615,"prevQuarterClose":1637.1339,"fiveDayClose":1833.2484,"twentyDayClose":1685.1011,"sixtyDayClose":1637.046,"secType":"PLATE","market":"US","turnoverRate":0.007083,"peRate":26.855529,"marketCap":1503745191758.25,"floatMarketCap":1479908328347.25,"timestamp":1771880399999,"nameCN":"美國抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":11,"down":7,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613731768","title":"輝瑞與 Sciwind Biosciences 達成糖尿病藥物交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2613731768","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613731768?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 11:24","pubTimestamp":1771903485,"startTime":"0","endTime":"0","summary":"路透上海2月24日 - 辉瑞PFE.N周二表示，已与Sciwind Biosciences公司签订了一项2型糖尿病治疗药物ecnoglutide的许可协议，如果达到阶段性目标，辉瑞将支付高达4.95亿美元的费用。根据与辉瑞公司的协议，Sciwind 公司有资格获得一笔金额未公开的预付费，以及与监管和销售相关的里程碑相关的额外付款。该协议涉及ecnoglutide在中国大陆的商业化。与诺和诺德的Ozempic、礼来的Mounjaro和innogen的efsubaglutide alfa不同，ecnoglutide将不会被纳入中国2型糖尿病治疗的国家医疗保险计划。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL4T3ZK0BE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE00BJJMRZ35.SGD","LU0198837287.USD","LU1057294990.SGD","IE00BKPKM429.USD","IE00BN29S564.USD","IE00BJLML261.HKD","LU0158827781.USD","LU0354030511.USD","LU1868836757.USD","LU2023250504.SGD","IE0002141913.USD","LU0170899867.USD","BK4581","IE00B1BXHZ80.USD","IE00BWXC8680.SGD","LU1988902786.USD","LU2168564149.EUR","LU2324357040.USD","LU2357305700.SGD","SG9999015986.USD","BK4516","LU0234572021.USD","LU2168564222.USD","BK4568","LU0868494617.USD","LU2265009873.SGD","LU1974910355.USD","91078","LU2756315664.SGD","IE00BJT1NW94.SGD","BK1589","LU0354030438.USD","LU2237443978.SGD","LU1983299246.USD","LU0708995401.HKD","LU2097828557.USD","SGXZ81514606.USD","BK4599","IE00BKDWB100.SGD","LU0502904849.HKD","LU0385154629.USD","LU0096364046.USD","LU2089284900.SGD","LU2462157665.USD","LU0455707207.USD","LU2471134796.USD","LU2213496289.HKD","SGXZ99366536.SGD","LU1035775433.USD","LU2089283258.USD","LU0058720904.USD","BK1583","LU2237443382.USD","LU0106261372.USD","LU0061475181.USD","LU1291159041.SGD","LU2237443465.HKD","ELIL","LU1323610961.USD","LU1868836914.USD","LU0289739699.SGD","LU1127390331.HKD","SG9999001176.USD","LU0882574055.USD","LU0079474960.USD","LU1366192091.USD","IE000M9KFDE8.USD","IE0001KFT4U8.USD","LU2063271972.USD","GB00BDT5M118.USD","LU1061106388.HKD","LU2361045086.USD","BK4588","LU0238689110.USD","LU1551013425.SGD","LU0256863811.USD","LU0640476718.USD","LLII","LU0109391861.USD","HK0000165453.HKD","LU2237443622.USD","LU1066053197.SGD","LU0820561818.USD","LU1868837300.USD","LU0466842654.USD","LU1814569148.SGD","LU1064131342.USD","LU2471134523.USD","SG9999011175.SGD","LU1069344957.HKD","SG9999002232.USD","LU2491050154.USD","IE00BLSP4452.SGD","LU2237438978.USD","LU0823416689.USD","LU0266013472.USD","LU2097828714.EUR","LU0210536198.USD","LU2108987350.USD","IE00BJJMRY28.SGD","LU0203201768.USD","LU2112291526.USD","LU0683600562.USD","LU0820562030.AUD","LU2264538146.SGD","LU1969619763.USD","BK4534","LU0122379950.USD","LU0203202063.USD","LU1894683348.USD","LU2552382058.USD","LU0417517546.SGD","LU1868837136.USD","BK4550","LU2242644610.SGD","LU2471134952.CNY","LU2023250330.USD","LU2237443895.HKD","LU0471298694.HKD","LU1720051108.HKD","LU1629891620.HKD","LU2746668461.USD","LU2111349929.HKD","LU0943347566.SGD","LU1868836591.USD","LU1720051017.SGD","IE0002270589.USD","LU1989771016.USD","LU0823434740.USD","LU0094547139.USD","LU0316494557.USD","LU1093756325.SGD","LU0306807586.USD","LU2468319806.SGD","LU0786609619.USD","LU2237443549.SGD","LU2552382132.HKD","LU1093756168.USD","LU1280957306.USD","LU1623119135.USD","LU1917777945.USD","IE00B1XK9C88.USD","LU0321505439.SGD","LU0689472784.USD","LU0256863902.USD","LU1883839398.USD","LU2361044949.HKD","IE00BFSS7M15.SGD","LU2488822045.USD","IE00BFSS8Q28.SGD","LU0320765992.SGD","LU2361044865.SGD","IE00B7KXQ091.USD","LU2456880835.USD","SG9999015945.SGD","IE00B19Z3581.USD","PFE","SG9999015978.USD","LLYX","LU1548497426.USD","SGXZ31699556.SGD","SG9999013999.USD","IE00B2B36J28.USD","IE0009355771.USD","LU2360106947.USD","SG9999014880.SGD","LU0353189763.USD","LU0823434583.USD","SGXZ57979304.SGD","SG9999002224.SGD","LU0964807845.USD","IE00B4R5TH58.HKD","IE00B19Z3B42.SGD","BK4592","IE00BBT3K403.USD","LU2236285917.USD","LU2328871848.SGD","LU2756315318.SGD","LU2417539215.USD","LU2896262040.SGD","SG9999018865.SGD","IE0005OL40V9.USD","IE0004445015.USD","LU0353189680.USD","LU0114720955.EUR","SG9999018857.SGD","SG9999014906.USD","SGXZ51526630.SGD","LU2089984988.USD","LU1145028129.USD","LU2471134879.HKD","LU0432979614.USD","IE00BJJMRX11.SGD","LU1804176565.USD","LU2168564065.EUR","BK4533","IE00BK4W5L77.USD","LU2087625088.SGD","SG9999014898.SGD","LU0471298777.SGD","LU0889565916.HKD","LU0323591593.USD","LU1232071149.USD","LU2097828474.EUR","LU2168564495.EUR","SG9999001176.SGD","LU2168563687.JPY","LU2552382215.SGD","LU0225283273.USD","LU0456855351.SGD","LU2097828631.EUR","ELIS","LU0225284248.USD","LU0672654240.SGD","LU1267930730.SGD","LU1066051498.USD","LU0820561909.HKD","LU2491050071.SGD","BK1161","LU0882574139.USD","LLYZ","LU1551013342.USD","LU2097828805.USD","SG9999015952.SGD","IE00BK4W5M84.HKD","LU2491049909.HKD","IE00B775H168.HKD","LU2211815571.USD","LU0306806265.USD","IE00BLSP4239.USD","BK4585","LU0787776722.HKD","LU1023059063.AUD","IE00BFTCPJ56.SGD","LU0985481810.HKD","LU0321505868.SGD","LU2023251221.USD","IE0004445239.USD","LU0225771236.USD","LU0320765059.SGD","IE00B4JS1V06.HKD","LU2746668974.SGD","LU2602419157.SGD","LU0158827948.USD","LU2106854487.HKD","LU2271345857.HKD","BK4007","LU0006306889.USD","LU0097036916.USD","LU2028103732.USD","LU2750360641.GBP","SG9999003800.SGD","LU1712237335.SGD","SG9999014914.USD","LU2461242641.AUD","LU2750360997.AUD","SG9999017495.SGD","LU1894683264.USD"],"gpt_icon":1},{"id":"2613897750","title":"先為達生物攜手輝瑞中國，達成埃諾格魯肽商業化戰略合作協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2613897750","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613897750?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 10:23","pubTimestamp":1771899780,"startTime":"0","endTime":"0","summary":"2月24日消息，杭州先为达生物科技股份有限公司与辉瑞中国今日宣布，双方就新一代偏向型GLP-1受体激动剂埃诺格鲁肽注射液 达成商业化战略合作协议。先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首付款、注册及销售里程碑付款。　　埃诺格鲁肽是由先为达生物自主研发的新一代cAMP偏向型GLP-1受体激动剂，将为2型糖尿病及长期体重管理相关患者提供更为精准的治疗方案。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-24/doc-inhnwrqu6119933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1894683348.USD","LU0058720904.USD","LU0321505439.SGD","BK4585","LU0170899867.USD","BK4581","LU1023059063.AUD","LU0306806265.USD","BK4007","IE00BLSP4239.USD","SG9999001176.USD","PFE","LU0985481810.HKD","BK4599","LU1066053197.SGD","LU0456855351.SGD","IE00B19Z3B42.SGD","LU0321505868.SGD","SG9999011175.SGD","SGXZ57979304.SGD","91078","IE00BBT3K403.USD","IE00BLSP4452.SGD","SG9999001176.SGD","LU0234572021.USD","BK4533","IE000M9KFDE8.USD","LU1066051498.USD","SG9999003800.SGD","SG9999013999.USD","LU0225284248.USD","BK4568","BK4534","BK4588","LU0306807586.USD","LU1883839398.USD","SG9999002232.USD","BK4550","SG9999002224.SGD","LU0122379950.USD","LU0289739699.SGD","LU1057294990.SGD","LU0225771236.USD","IE00B19Z3581.USD","LU1894683264.USD","IE0002270589.USD","LU0868494617.USD","BK4592"],"gpt_icon":1},{"id":"2613757536","title":"拜耳就前列腺癌藥物營銷問題起訴強生","url":"https://stock-news.laohu8.com/highlight/detail?id=2613757536","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613757536?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 10:03","pubTimestamp":1771898618,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","LU2129689514.USD","LU0889566641.SGD","IE00B3T34201.USD","LU2468319806.SGD","IE00BFXG1179.USD","JNJ","LU0466842654.USD","LU1894683264.USD","IE00BZ1G4Q59.USD","BK4504","SG9999002232.USD","IE0001KFT4U8.USD","BK4534","LU2133065610.SGD","LU0345770308.USD","IE00BJT1NW94.SGD","LU0985320562.USD","LU1280957306.USD","BK4585","IE00BBT3K403.USD","LU1244550577.SGD","IE00B2B36J28.USD","LU1506573853.SGD","LU1914381329.SGD","LU0114720955.EUR","LU0882574055.USD","BK4550","IE0002141913.USD","LU1059921491.USD","LU0912757837.SGD","BK4568","LU0320765646.SGD","LU1074936037.SGD","LU0792757196.USD","BK4533","LU0345769128.USD","LU1196500208.SGD","LU0122379950.USD","LU1244550494.USD","LU2112291526.USD","BK4588","IE0002270589.USD","LU0234570918.USD","LU1732800096.USD","LU1674673428.USD","LU2505996509.AUD","LU1929549753.HKD","LU1674673691.USD","IE00B42XCP33.USD"],"gpt_icon":0},{"id":"2613527777","title":"BRIEF-中國先為達生物將向輝瑞收取至多4.95億美元，輝瑞獲其減肥藥在中國大陸的獨家商業化權益","url":"https://stock-news.laohu8.com/highlight/detail?id=2613527777","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613527777?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 09:56","pubTimestamp":1771898177,"startTime":"0","endTime":"0","summary":"BRIEF-中国先为达生物将向辉瑞收取至多4.95亿美元，辉瑞获其减肥药在中国大陆的独家商业化权益路透2月24日 - 中国生物科技公司先为达生物:中国生物科技公司先为达生物：将降糖减重药埃诺格鲁肽注射液在中国大陆的独家商业化权益授予辉瑞PFE.N先为达生物：将有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首付款、注册及销售里程碑付款浏览公告详情，请点击此处 (发稿 徐凯文) ((Kaiwen.Xu@thomsonreuters.com;))","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL4T3ZK06S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4585","LU1894683264.USD","IE00B19Z3581.USD","LU0321505868.SGD","LU0225771236.USD","IE000M9KFDE8.USD","BK4007","BK4592","LU0234572021.USD","IE00B19Z3B42.SGD","BK4550","LU1057294990.SGD","91078","IE0002270589.USD","IE00BBT3K403.USD","BK4581","LU0868494617.USD","BK4599","SG9999011175.SGD","LU1883839398.USD","PFE","BK4588","SG9999001176.USD","LU0058720904.USD","LU0321505439.SGD","BK4568","LU0225284248.USD","BK4533","LU0456855351.SGD","LU1066051498.USD","IE00BLSP4452.SGD","LU1894683348.USD","LU0170899867.USD","LU0306807586.USD","SG9999003800.SGD","SG9999002232.USD","LU1023059063.AUD","LU0306806265.USD","SG9999001176.SGD","SGXZ57979304.SGD","SG9999002224.SGD","LU0289739699.SGD","LU0985481810.HKD","LU1066053197.SGD","SG9999013999.USD","IE00BLSP4239.USD","LU0122379950.USD"],"gpt_icon":0},{"id":"2613375233","title":"專欄-諾華公司悄然解決亨麗埃塔-拉克斯訴訟案，家族的法律推動力日益壯大","url":"https://stock-news.laohu8.com/highlight/detail?id=2613375233","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613375233?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 09:33","pubTimestamp":1771896800,"startTime":"0","endTime":"0","summary":"路透2月24日 - 上周，诺华公司就亨丽埃塔-拉克斯遗产提起的诉讼达成和解，解决了该公司未经许可使用拉克斯的 \"不死 \"细胞并从中获利的指控。这项保密协议并没有结束拉克斯继承人更广泛的法律诉讼。从法庭记录的寥寥几笔来看，诺华公司似乎并不愿意就此案提起诉讼。针对该公司的诉讼仍悬而未决。据法院文件显示，在第四巡回法院驳回强制令申请后，Ultragenyx 公司和拉克斯遗产暂停了诉讼程序，以便进行和解谈判。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL4S3ZK05H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.USD","LU2720916845.USD","LU2764263039.SGD","IE00B1BXHZ80.USD","LU0868494617.USD","LU0823416689.USD","LU2063271972.USD","LU2211814178.USD","LU0985481810.HKD","LU1066053197.SGD","BK4585","LU1670627923.USD","LU0114720955.EUR","LU0640476718.USD","LU0266013472.USD","LU0170899867.USD","BK4139","LU1803068623.USD","LU1839511570.USD","IE00BKPKM429.USD","LU1923621640.USD","LU2087621335.USD","LU1989771016.USD","LU1670628061.USD","IE00BFTCPJ56.SGD","LU2264538146.SGD","LU0316494557.USD","LU0096362180.USD","LU0456855351.SGD","LU0342679015.USD","LU0345770308.USD","IE0002141913.USD","LU0321505868.SGD","LU1623119135.USD","LU2125909916.SGD","LU1061106388.HKD","LU2764263203.CNY","LU0208291251.USD","IE00BJJMRZ35.SGD","SG9999002224.SGD","IE0009355771.USD","LU2089984988.USD","LU0957791311.USD","IE00B19Z8W00.USD","LU2125910179.SGD","BK4535","LU0225284248.USD","LU2360108059.USD","LU1983299246.USD","LU2041044095.USD","IE0002270589.USD","LU2543165471.USD","LU1791710582.SGD","SG9999002232.USD","LU1894683348.USD","LU0070302665.USD","LU2125909247.SGD","LU1633808545.USD","SG9999013999.USD","BK4583","BK4599","LU0321505439.SGD","LU2125910336.SGD","LU0234572021.USD","LU2468319806.SGD","LU0320765489.SGD","BK4548","LU0289739699.SGD","LU1023059063.AUD","LU0225771236.USD","GB00BDT5M118.USD","LU1923622291.USD","LU2125909759.SGD","NVS","BK4121","BK4588","LU1057294990.SGD","SG9999001176.SGD","LU1720051108.HKD","BK4568","IE00B19Z8X17.USD","LU1815333072.USD","LU2298321311.HKD","LU0306807586.USD","IE0034235188.USD","LU1153585028.USD","LU2357305700.SGD","LU0306806265.USD","LU1923622614.USD","LU1854104046.USD","LU1720051017.SGD","LU1548497426.USD","LU2211815571.USD","IE00BLSP4239.USD","LU0011850046.USD","IE00B19Z9505.USD","LU2125909593.SGD","SGXZ57979304.SGD","IE00BBT3K403.USD","LU1066051498.USD","LU1791710400.SGD","LU2764262908.HKD","IE000M9KFDE8.USD","IE00B4R5TH58.HKD","IE00B19Z3B42.SGD","BK4007","LU0528227936.USD","LU1280957306.USD","LU1291159041.SGD","LU2433249047.HKD","BK4533","SG9999011175.SGD","IE00BLSP4452.SGD","SG9999003800.SGD","BK4581","BK4534","BK4592","LU1883839398.USD","BK4550","BK4566","LU1988902786.USD","IE00BJT1NW94.SGD","LU0058720904.USD","IE00B2B36J28.USD","LU2112291526.USD","LU1894683264.USD","LU0122379950.USD","LU1064131342.USD","LU0882574055.USD","IE00B19Z3581.USD","LU1854103824.USD","LU0557290698.USD","LU0061474960.USD","LU1712237335.SGD","LU0345770993.USD","LU2092937221.SGD"],"gpt_icon":0},{"id":"1110833815","title":"杭州Sciwind生物與輝瑞中國就新一代Ecnoglutide注射劑商業化達成戰略合作協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1110833815","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110833815?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 09:30","pubTimestamp":1771896617,"startTime":"0","endTime":"0","summary":"杭州Sciwind生物科技公司与辉瑞中国已正式签署战略合作协议，共同推进新一代Ecnoglutide注射剂的商业化进程。此次合作旨在整合双方在研发与市场渠道方面的优势，加速该创新药物在中国市场的应用与推广。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002224.SGD","LU1066051498.USD","02252","IE00BLSP4239.USD","SG9999002232.USD","SGXZ57979304.SGD","LU0321505439.SGD","LU1883839398.USD","SG9999001176.SGD","BK4585","BK4581","LU0985481810.HKD","LU1894683348.USD","IE00BBT3K403.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU0170899867.USD","LU0225284248.USD","IE00B19Z3581.USD","BK4599","LU1894683264.USD","BK4592","SG9999011175.SGD","LU0058720904.USD","LU1066053197.SGD","LU0456855351.SGD","BK4007","BK4534","LU0225771236.USD","LU1023059063.AUD","PFE","LU1057294990.SGD","LU0306806265.USD","LU0289739699.SGD","LU0306807586.USD","BK4533","BK4588","BK4550","IE000M9KFDE8.USD","LU0234572021.USD","BK4568","LU0868494617.USD","SG9999003800.SGD","SG9999013999.USD","LU0321505868.SGD","IE00BLSP4452.SGD","SG9999001176.USD","LU0122379950.USD"],"gpt_icon":0},{"id":"1135793155","title":"Vir Biotechnology公布企業動態及2025年第四季度與全年財務業績","url":"https://stock-news.laohu8.com/highlight/detail?id=1135793155","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135793155?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 06:15","pubTimestamp":1771884909,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc.（简称：Vir）近日发布了公司最新运营进展，并同步披露了2025年第四季度及全年的财务报告。此次公布的内容涵盖了公司在研发管线、临床进展及财务状况等方面的关键信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","VIR","BK4139","BK4585","BK4568"],"gpt_icon":0},{"id":"1132986101","title":"Vir Biotechnology：在≥3000微克/公斤Q3W劑量隊列中，VIR-5500實現82%的PSA50及53%的PSA90下降率，並獲得RECIST可評估的客觀緩解","url":"https://stock-news.laohu8.com/highlight/detail?id=1132986101","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132986101?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 06:06","pubTimestamp":1771884374,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc. 公布的最新数据显示，在其VIR-5500药物的临床研究中，接受剂量不低于3000微克/公斤、每三周一次（Q3W）给药方案的队列取得了显著成果。该队列患者的前列腺特异性抗原（PSA）水平出现深度下降，其中PSA50（即PSA水平较基线下降≥50%）的应答率达到82%，而PSA90（即PSA水平较基线下降≥90%）的应答率也高达53%。此外，根据实体瘤疗效评价标准（RECIST）进行评估，该队列中观察到了客观缓解，表明药物具有抗肿瘤活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4585","VIR","BK4535","BK4139"],"gpt_icon":0},{"id":"1159972069","title":"Vir Biotechnology發布靶向PSMA的Pro-Xten®雙遮蔽T細胞銜接器VIR-5500治療轉移性前列腺癌的積極1期最新數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1159972069","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159972069?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 06:03","pubTimestamp":1771884192,"startTime":"0","endTime":"0","summary":"Vir Biotechnology宣布其靶向前列腺特异性膜抗原（PSMA）的Pro-Xten®双遮蔽T细胞衔接器VIR-5500，在治疗转移性前列腺癌患者的1期临床试验中取得积极的最新结果。该创新疗法通过双重遮蔽技术精准激活T细胞对抗肿瘤细胞，最新数据显示其在安全性和耐受性方面表现良好，同时展现出令人鼓舞的抗肿瘤活性。这一进展为晚期前列腺癌患者提供了新的治疗希望，也标志着双特异性T细胞衔接器在实体瘤领域的重要突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4585","VIR","BK4535","BK4139"],"gpt_icon":0},{"id":"1129173743","title":"Vir Biotechnology, Inc.：推進劑量擴展隊列，計劃於2027年啓動註冊性試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1129173743","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129173743?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 06:03","pubTimestamp":1771884190,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc. 宣布，其研发项目在剂量扩展队列方面取得了积极进展。公司已制定明确规划，目标在2027年正式启动关键的注册性临床试验。这一战略步骤标志着其在核心疗法开发道路上迈出了重要一步，为后续的监管审批和潜在商业化奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","VIR","BK4568","BK4535"],"gpt_icon":0},{"id":"2613758121","title":"安斯泰來與維爾合作開發前列腺癌實驗藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2613758121","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613758121?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 06:00","pubTimestamp":1771884021,"startTime":"0","endTime":"0","summary":"安斯泰来与维尔合作开发前列腺癌实验药物路透2月23日 - 日本安斯泰来 4503.T 公司和Vir生物技术 VIR.O 公司周一表示，它们将共同开发美国药物开发商的前列腺癌实验药物并将其商业化。两家公司表示，安斯泰来公司将领导 VIR-5500 在美国的商业化，并拥有美国以外的独家代理权，Vir 公司保留在美国共同推广的选择权。VIR-5500作为晚期转移性前列腺癌的实验性治疗药物，目前正处于早期1期试验阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL4S3ZJ1Q4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4568","BK4535","VIR"],"gpt_icon":0},{"id":"1141530990","title":"安斯泰來：有望獲得最高13.7億美元額外開發、監管及銷售里程碑款項","url":"https://stock-news.laohu8.com/highlight/detail?id=1141530990","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141530990?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 06:00","pubTimestamp":1771884015,"startTime":"0","endTime":"0","summary":"安斯泰来制药公司宣布，其合作协议条款可能为其带来高达13.7亿美元的额外资金。这笔款项将根据药物开发进展、监管审批达成情况以及市场销售表现等里程碑事件分批获得。此次潜在的财务注入凸显了公司在创新疗法领域的战略布局，也为后续研发提供了资金保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","BK4535","BK4585","VIR"],"gpt_icon":0},{"id":"1120141495","title":"安斯泰來製藥與Vir Biotechnology達成全球戰略合作 共同推進前列腺癌治療藥物VIR-5500研發","url":"https://stock-news.laohu8.com/highlight/detail?id=1120141495","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120141495?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 06:00","pubTimestamp":1771884015,"startTime":"0","endTime":"0","summary":"安斯泰来制药公司宣布与生物技术企业Vir Biotechnology, Inc.达成一项全球战略合作协议，双方将携手推进创新药物VIR-5500在前列腺癌治疗领域的研发进程。此次合作整合了安斯泰来在肿瘤治疗领域的深厚积淀与Vir Biotechnology在抗体药物开发方面的前沿技术，旨在加速该候选药物的临床研究与国际市场布局。通过资源互补与协同创新，两家企业期望为全球前列腺癌患者提供更有效的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","VIR","BK4535","BK4585","BK4139"],"gpt_icon":0},{"id":"1169919771","title":"安斯泰來與Vir Biotechnology達成協議：後者將獲3.35億美元首付款及近期里程碑款項，雙方在美盈虧平分","url":"https://stock-news.laohu8.com/highlight/detail?id=1169919771","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169919771?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 06:00","pubTimestamp":1771884014,"startTime":"0","endTime":"0","summary":"安斯泰来制药集团宣布，与Vir Biotechnology, Inc.达成一项合作协议。根据协议，Vir Biotechnology将获得总计3.35亿美元的款项，其中包括首付款以及近期可达成的里程碑付款。\n此外，双方约定将平等分摊其合作产品在美国市场的利润与亏损。这一合作模式旨在平衡双方的风险与收益，共同推进相关产品的开发与商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4585","VIR","BK4535","BK4139"],"gpt_icon":0},{"id":"1198799946","title":"安斯泰來：根據Vir Biotechnology與賽諾菲的授權協議條款，部分合作收益將分享給賽諾菲","url":"https://stock-news.laohu8.com/highlight/detail?id=1198799946","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198799946?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 06:00","pubTimestamp":1771884012,"startTime":"0","endTime":"0","summary":"根据Vir Biotechnology与赛诺菲达成的授权协议条款，特定合作项目所产生的部分收益将由Vir Biotechnology与赛诺菲共同分享。安斯泰来对此进行了说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4535","BK4139","BK4585","BK4568"],"gpt_icon":0},{"id":"2613873230","title":"美國 FDA 局長馬卡里説，FDA 支持 mRNA 疫苗，但美國納税人不應承擔費用","url":"https://stock-news.laohu8.com/highlight/detail?id=2613873230","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613873230?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 04:11","pubTimestamp":1771877495,"startTime":"0","endTime":"0","summary":"美国 FDA 局长马卡里说，FDA 支持 mRNA 疫苗，但美国纳税人不应承担费用马卡里说，FDA 支持 mRNA 疫苗，但不支持纳税人的资助马卡里为 HHS 削减 mRNA 经费的决定辩护马卡里认为，公司有能力负担 mRNA 研究费用Ahmed Aboulenein. 在我任职之初，我们已经批准了两种 mRNA 疫苗。马卡里称美国因资金问题拒绝资助MRNA马卡里为美国卫生与公众服务部 8 月份决定  停止其生物医学研究部门的 mRNA 疫苗开发活动辩护。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL4S3ZJ1JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0985481810.HKD","SG9999001176.SGD","LU2125154935.USD","LU0861579265.USD","LU0106261372.USD","LU0965508806.USD","BK4548","IE00B1BXHZ80.USD","LU1917777945.USD","LU0965509101.SGD","LU1989772923.USD","LU2361044949.HKD","SG9999002232.USD","SG9999013999.USD","IE00BLSP4239.USD","LU0320765489.SGD","IE00BN8TJ469.HKD","LU1929549753.HKD","LU2023250843.SGD","BK4559","IE00B2B36J28.USD","LU0203347892.USD","LU0225284248.USD","SG9999001440.SGD","SG9999014542.SGD","LU1093756168.USD","LU1699723380.USD","LU1069347547.HKD","LU0238689110.USD","LU0432979614.USD","LU0130102774.USD","LU1989772840.SGD","SG9999015358.SGD","LU1585245621.USD","LU1066051811.HKD","BK4592","LU1883839398.USD","LU1934455194.USD","LU1057294990.SGD","LU0006306889.USD","SG9999003800.SGD","LU0477156953.USD","LU2324357040.USD","LU1116320737.USD","LU1023059063.AUD","MRK","LU1061106388.HKD","LU1894683348.USD","LU1066051498.USD","IE00BLSP4452.SGD","LU2360032135.SGD","LU0266013472.USD","LU1941712348.USD","BK4533","LU1162221912.USD","LU1037948541.HKD","LU1291159041.SGD","BK4588","LU0098860793.USD","LU0306806265.USD","LU0965509010.AUD","LU0321505868.SGD","BK4534","MRNY","IE00B19Z3581.USD","LU2023250504.SGD","LU0265550946.USD","LU0130517989.USD","MRNA","LU1116320901.HKD","BK4551","LU2361045086.USD","SG9999015341.SGD","LU0211331839.USD","LU0203345920.USD","LU1066051225.USD","LU0122379950.USD","IE0009355771.USD","LU0648001328.SGD","SG9999002224.SGD","SG9999001176.USD","LU0170899867.USD","SGXZ57979304.SGD","BK4599","LU1093756325.SGD","BK4568","LU1974910355.USD","LU0321505439.SGD","SG9999014559.SGD","BK4007","LU0965509283.SGD","LU1430594728.SGD","LU0225771236.USD","LU0265550359.USD","IE0002270589.USD","LU1035773651.USD","IE000M9KFDE8.USD","LU1571399168.USD","SG9999014567.USD","BK4516","SG9999014575.USD","LU1066053197.SGD","IE00BBT3K403.USD","LU2461242641.AUD","LU2089984988.USD","LU0058720904.USD","LU1894683264.USD","BK4581","BK4532","IE00B4R5TH58.HKD","LU1983299246.USD","LU1941712264.USD","MRNX","SG9999011175.SGD","LU2106854487.HKD","BK4501","BK4585","LU0070302665.USD","IE0002141913.USD","IE00B19Z3B42.SGD","LU0456855351.SGD","LU2125154778.USD","LU2468319806.SGD","LU0234572021.USD","LU1934455863.HKD","LU0868494617.USD","IE00BFTCPJ56.SGD","LU2112291526.USD","LU1201861249.SGD","IE00BJJMRZ35.SGD","BK4139","LU0320765646.SGD","LU1989771016.USD","IE00BJT1NW94.SGD","LU0980610538.SGD","LU0306807586.USD","LU1934455277.USD","LU2361044865.SGD","BK4550","IE00BSNM7G36.USD","LU1037948897.HKD","LU0985320562.USD","LU0208291251.USD"],"gpt_icon":1},{"id":"1128631880","title":"歐盟批准皮下注射版Rybrevant®▼（Amivantamab）用於晚期EGFR突變非小細胞肺癌患者的每三周及每四周給藥方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1128631880","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128631880?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 00:21","pubTimestamp":1771863672,"startTime":"0","endTime":"0","summary":"欧盟委员会已正式批准强生公司旗下皮下注射制剂Rybrevant®▼（Amivantamab）用于治疗晚期EGFR突变非小细胞肺癌患者，新增每三周一次和每四周一次的给药方案。这一决定为患者提供了更为灵活的治疗选择，有望改善治疗便利性与生活质量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0689626769.HKD","IE00BGHQF631.EUR","LU2347655156.SGD","LU2471134952.CNY","LU1430594728.SGD","LU2592432038.USD","IE00BSNM7G36.USD","LU0640476718.USD","BK4532","IE00B3PB1722.GBP","LU0889566641.SGD","LU1732800096.USD","IE0002141913.USD","LU0795875086.SGD","IE00BJT1NW94.SGD","LU2471134523.USD","LU1894683264.USD","IE00B1BXHZ80.USD","LU1935042991.SGD","LU2750360641.GBP","IE00B4R5TH58.HKD","LU1244550221.USD","IE00B42XCP33.USD","IE0001KFT4U8.USD","LU1261432733.SGD","IE00BLSP4239.USD","LU0345770993.USD","LU2471134879.HKD","LU0124676726.USD","LU0345770308.USD","LU1674673691.USD","BK4007","BK4585","LU2430703178.SGD","LU1778281490.HKD","IE00BN8TJ469.HKD","LU2505996681.GBP","LU0432979614.USD","LU1585245621.USD","IE0002270589.USD","IE00B3T34201.USD","IE000M9KFDE8.USD","LU2129689605.HKD","LU2430703095.HKD","LU1267930813.SGD","IE00B19Z3581.USD","LU0912757837.SGD","LU1280957306.USD","BK4568","LU1732799900.SGD","LU1221951129.SGD","IE00BZ1G4Q59.USD","LU1032466523.USD","LU0787776722.HKD","BK4534","IE0009355771.USD","LU0234570918.USD","LU2430703251.USD","LU2468319806.SGD","BK4581","LU0114720955.EUR","BK4588","LU2129689514.USD","LU0058720904.USD","SG9999002232.USD","IE00BVYPNV92.GBP","LU0466842654.USD","LU0203345920.USD","LU1066053197.SGD","SG9999002224.SGD","LU2112291526.USD","IE0034235303.USD","LU2505996509.AUD","LU0795875169.SGD","IE00BLSP4452.SGD","IE00BVYPNW00.USD","LU1244550577.SGD","LU1074936037.SGD","IE00BKVL7J92.USD","LU0320765646.SGD","BK4592","LU2089984988.USD","BK4504","BK4550","IE00B19Z3B42.SGD","IE00BFXG1179.USD","LU1057294990.SGD","LU2133065610.SGD","IE00BFTCPJ56.SGD","LU1914381329.SGD","LU0098860793.USD","LU0792757196.USD","LU1066051225.USD","LU1066051498.USD","LU0985320562.USD","JNJ","LU1894683348.USD","LU0345769631.USD","LU0683600562.USD","LU2471134796.USD","LU1221951046.USD","LU1023059063.AUD","LU1674673428.USD","LU1506573853.SGD","IE00B7SZLL34.SGD","IE00BBT3K403.USD","LU0345769128.USD","LU0882574055.USD","BK4559","LU1244550494.USD","LU2602419157.SGD","LU1032955483.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0289739699.SGD","LU1162221912.USD","LU2750360997.AUD","LU1196500208.SGD","LU0070217475.USD","LU0234572021.USD","LU1496350502.SGD","LU1983299246.USD","LU2129689431.USD","IE00BDGV0183.EUR","LU1059921491.USD","LU1718418525.SGD","SG9999001440.SGD","LU1061106388.HKD","LU1066051811.HKD","LU1929549753.HKD","LU0203347892.USD","BK4533","LU0122379950.USD"],"gpt_icon":0},{"id":"1100354748","title":"強生皮下注射版Amivantamab獲准用於所有先前獲批的靜脈注射適應症","url":"https://stock-news.laohu8.com/highlight/detail?id=1100354748","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100354748?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 00:21","pubTimestamp":1771863672,"startTime":"0","endTime":"0","summary":"强生公司宣布，其皮下注射（SC）剂型的Amivantamab现已获得授权，可用于所有先前已获批的静脉注射（IV）Amivantamab的适应症。这一授权意味着该药物在更便捷的给药方式下，其应用范围得到了正式扩展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00BBT3K403.USD","LU0234572021.USD","IE00B3PB1722.GBP","LU0432979614.USD","LU0795875169.SGD","LU1983299246.USD","LU0345769631.USD","BK4592","IE0001KFT4U8.USD","IE00BN8TJ469.HKD","LU1023059063.AUD","LU1496350502.SGD","LU0114720955.EUR","LU2129689431.USD","LU1894683264.USD","BK4559","LU2505996681.GBP","IE00BFXG1179.USD","IE00B19Z3581.USD","LU0124676726.USD","BK4550","LU2089984988.USD","BK4585","LU0345770993.USD","LU0070217475.USD","LU2129689605.HKD","IE00B4R5TH58.HKD","BK4534","LU1074936037.SGD","LU0683600562.USD","IE0002270589.USD","IE0002141913.USD","LU1244550494.USD","BK4533","LU1162221912.USD","JNJ","LU1280957306.USD","LU1066051498.USD","LU2471134796.USD","IE00BVYPNW00.USD","LU2112291526.USD","LU0345769128.USD","IE00BZ1G4Q59.USD","LU2750360997.AUD","SG9999002224.SGD","LU0689626769.HKD","LU0320765646.SGD","IE00B1BXHZ80.USD","LU1057294990.SGD","LU2505996509.AUD","LU2129689514.USD","SG9999002232.USD","IE000M9KFDE8.USD","BK4568","LU0912757837.SGD","BK4532","LU2750360641.GBP","LU1066051225.USD","LU1430594728.SGD","LU1732800096.USD","LU1894683348.USD","LU2347655156.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00B3T34201.USD","BK4581","LU1585245621.USD","IE00B42XCP33.USD","LU2471134879.HKD","LU0787776722.HKD","IE00BJT1NW94.SGD","IE00BLSP4452.SGD","LU0122379950.USD","LU0882574055.USD","LU1059921491.USD","LU0098860793.USD","LU1929549753.HKD","LU2592432038.USD","LU2430703095.HKD","LU1066051811.HKD","LU0795875086.SGD","LU0203347892.USD","LU2471134523.USD","LU1244550577.SGD","LU2468319806.SGD","LU0640476718.USD","LU1221951129.SGD","SG9999001440.SGD","LU0345770308.USD","LU0792757196.USD","LU1914381329.SGD","LU1267930813.SGD","IE00BKVL7J92.USD","LU1935042991.SGD","LU2430703251.USD","LU1221951046.USD","LU0289739699.SGD","IE00B2B36J28.USD","LU0889566641.SGD","IE00B7SZLL34.SGD","IE0034235303.USD","LU1032466523.USD","LU2430703178.SGD","LU1732799900.SGD","LU0234570918.USD","BK4588","IE00BFTCPJ56.SGD","LU1674673428.USD","LU2471134952.CNY","IE00BSNM7G36.USD","LU1196500208.SGD","LU0058720904.USD","IE00BDGV0183.EUR","LU1718418525.SGD","LU2133065610.SGD","LU1032955483.USD","LU2602419157.SGD","LU1261432733.SGD","LU1674673691.USD","BK4504","LU1066053197.SGD","LU1506573853.SGD","IE00B19Z3B42.SGD","IE00BVYPNV92.GBP","LU1778281490.HKD","LU1244550221.USD","LU1061106388.HKD","LU0466842654.USD","LU0985320562.USD","LU0203345920.USD","IE00BGHQF631.EUR","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"2613733725","title":"拜耳起訴強生公司虛假營銷前列腺癌藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2613733725","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613733725?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 00:09","pubTimestamp":1771862994,"startTime":"0","endTime":"0","summary":"更新版 1-拜耳起诉强生公司虚假营销前列腺癌药物改写；在诉状中增加指控内容，将日期线改为纽约路透纽约2月23日 - 拜耳BAYGn.DE周一起诉强生JNJ.N，指控这家竞争对手制药商对一种治疗前列腺癌的药物进行虚假宣传。拜耳寻求三倍赔偿、追回所谓的不当得利，并要求法院下达禁令，制止强生公司所谓的虚假广告。强生公司没有立即回应置评请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL4T3ZJ17A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2505996509.AUD","LU0124676726.USD","LU0345770993.USD","LU1496350502.SGD","LU0795875086.SGD","LU1066053197.SGD","LU1718418525.SGD","LU1674673428.USD","BK4588","LU0795875169.SGD","LU1221951129.SGD","IE00BJJMRZ35.SGD","LU1267930813.SGD","IE00BGHQF631.EUR","LU2602419157.SGD","BK4559","IE00B4R5TH58.HKD","IE00BLSP4239.USD","LU1732799900.SGD","LU1061106388.HKD","IE00BBT3K403.USD","IE0002141913.USD","LU0234570918.USD","LU2129689431.USD","LU0787776722.HKD","LU1261432733.SGD","LU0114720955.EUR","LU2750360641.GBP","BK4592","LU1914381329.SGD","LU0070217475.USD","LU1674673691.USD","LU0912757837.SGD","BK4532","LU0203345920.USD","LU2430703251.USD","IE00BDGV0183.EUR","LU1032466523.USD","IE00B1BXHZ80.USD","LU1032955483.USD","IE00BSNM7G36.USD","IE00B2B36J28.USD","LU1023059063.AUD","JNJ","LU1585245621.USD","LU2505996681.GBP","BK4585","LU1059921491.USD","LU1280957306.USD","BK4007"],"gpt_icon":0},{"id":"2613782741","title":"肺病藥物後期試驗失敗，歌美颯生物股價暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2613782741","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613782741?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 21:33","pubTimestamp":1771853601,"startTime":"0","endTime":"0","summary":"更新版 3-肺病药物后期试验失败，歌美飒生物股价暴跌试验结果公布后股价下跌 80%首席执行官认为综合研究数据具有潜力，将提交 FDA 审议Gossamer 将与该机构会面，暂停另一项研究的入组更新股价，在第 6 段添加首席执行官评论，在第 8 段添加分析师评论Sahil  Pandey/Siddhi Mahatole路透2月23日 - Gossamer Bio公司的GOSS.O实验性疗法在一项晚期研究中未能显著提高罕见肺病患者的运动能力，导致该药物开发商的股价周一下跌了80%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL4T3ZJ0X7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","BK4568","LU0265550359.USD","BK4592","LU2505996681.GBP","IE00BSNM7G36.USD","LU1066051811.HKD","SG9999015358.SGD","GOSS","LU1059921491.USD","IE0002141913.USD","LU1894683348.USD","LU1244550494.USD","LU1983299246.USD","LU0058720904.USD","LU1934455277.USD","LU1201861249.SGD","IE0009355771.USD","IE00B1BXHZ80.USD","LU1066051225.USD","MRK","IE00BN8TJ469.HKD","LU1989772840.SGD","LU2471134879.HKD","LU1069347547.HKD","BK4516","IE0034235303.USD","LU0477156953.USD","LU2361044865.SGD","LU1261432733.SGD","IE00BFTCPJ56.SGD","LU0792757196.USD","LU0320765489.SGD","SGXZ57979304.SGD","BK4533","BK4581","LU1267930813.SGD","LU1699723380.USD","SG9999001176.USD","LU0208291251.USD","IE00B19Z3581.USD","BK4534","LU2360032135.SGD","BK4504","LU2592432038.USD","LU1934455194.USD","JNJ","IE000M9KFDE8.USD","IE00BGHQF631.EUR","IE00B42XCP33.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":124,"code":"91000000","status":"200"}]}}